FDA Launches Unified Adverse Event Tracking System, Critics Cite Unresolved Transparency Issues

Introduction

The Food and Drug Administration (FDA) launched a new centralized database on Tuesday, March 10, aimed at improving the monitoring of side effects from drugs, vaccines and other regulated products. The FDA Adverse Event Monitoring System (AEMS) consolidates several legacy platforms, including the Vaccine Adverse Event Reporting System, into a single, modern interface. FDA Commissioner Dr. Marty Makary stated the previous systems were “outdated and fragmented and made important data difficult to access.” ^[1][2]

According to the agency, AEMS will provide public access to real-time data updates, replacing quarterly releases, and is projected to save taxpayers approximately $120 million over the next five years. The system will be powered by artificial intelligence to analyze reports. The rollout was announced under the leadership of Health Secretary Robert F. Kennedy Jr., who had previously promised “radical transparency” in federal health agencies. ^[3][4]

FDA Unveils New AEMS Database, Promising Real-Time Data and Efficiency

The AEMS platform merges the FDA’s previously separate adverse event reporting systems for drugs, vaccines, biologics, cosmetics, color additives, animal drugs and foods. According to the agency, these databases collectively processed around six million reports annually. Makary described the old systems as “clunky” and stated they “wasted millions of taxpayer dollars and created blind spots in our postmarket surveillance.” ^[5]

By the end of May 2026, AEMS is scheduled to incorporate adverse event data from all FDA-regulated product categories, including human foods, dietary supplements, tobacco products and medical devices. An FDA official, quoted by Fox News, said a future phase will include a user-friendly front-end to simplify report submission, addressing estimates that 80% of adverse events were never formally reported due to system complexity. ^[6][7]

Advocates and Critics React to New System’s Potential and Shortcomings

Initial reactions from patient advocacy groups and independent researchers were mixed. Christopher Dreisbach, legal affairs director for the vaccine injury group React19, called AEMS a “potential step forward” from what he described as a “Kafkaesque status quo,” where reports are often dismissed as unreliable. ^[5]

Other critics expressed deeper reservations. Karl Jablonowski, Ph.D., senior research scientist for Children’s Health Defense, questioned the system’s reliance on AI for decision-making.

“Decisions made by humans are trackable, accountable and inquirable. With AI, it is not so easy to identify the genesis of decisions and accountability doesn’t exist,” Jablonowski said.  Albert Benavides, founder of VAERSaware.com, was more blunt, stating the new dashboard appears to be a ‘rebrand’ of the old FAERS system with minimal added functionality. ^[5][8]

Historical Problems with VAERS and Calls for Transparency

The launch follows years of documented problems with VAERS, the primary public-facing vaccine safety database. A 2023 investigation by The BMJ revealed the government operated two VAERS systems: one public-facing database and a private back-end system containing corrections and updates, including reports of deaths that occurred after an initial injury. The investigation also identified issues with disappearing reports and data errors. ^[9]

During two U.S. House of Representatives hearings in 2024, witnesses testified that inadequate vaccine safety surveillance had “jeopardized” Americans’ health during the Wuhan coronavirus (COVID-19) vaccine rollout. In a separate account, retired Dr. Danice Hertz reported it took three years and 11 separate submissions to VAERS before she received a follow-up call from the Centers for Disease Control and Prevention (CDC). A CDC employee told her the agency was “swamped with reports of injury.” ^[5][10]

Specific Criticisms of AEMS Design and Data Limitations

Technical analysts who have reviewed the AEMS interface have identified several specific design shortcomings. Benavides noted the system lacks the “free text narrative” section customary in VAERS reports, which allowed submitters to provide critical context like vaccine history, lab results, and concomitant medications. ^[5]

Benavides also stated that data fields for adverse event severity levels – such as “Hospitalization,” “Life Threatening” or “Death” — are absent. The date of death, commonly included in VAERS, is “non-existent” in the new platform, and vaccine lot number information is “buried under an additional layer of clicks.” Furthermore, the system caps data downloads for researchers at 10,000 records at one time, which Benavides said would hamper meaningful analysis. ^[5]

Core Issue of Follow-Up and Verification Remains Unaddressed

Multiple critics emphasized that streamlining data entry does not solve the fundamental problem of inadequate investigation into reports. Christopher Dreisbach of React19 stated, “Streamlining is only one piece of what is needed. The bigger issue is follow-up and verification.” He explained that clinicians often assume reporting triggers an investigation, but “in reality, most reports simply become entries in a database.” ^[5]

Dr. Joel Wallskog, co-chair of React19, argued that for AEMS to succeed, reporting must be mandatory for medical providers and healthcare organizations, with penalties for non-compliance. Critics also noted that a key near-real-time monitoring tool, the Vaccine Safety Datalink, which tracks data on 10 million people, is not included within the new AEMS platform. ^[5][11]

Conclusion

The FDA’s launch of the AEMS database represents a technological consolidation of its safety monitoring tools, promising efficiency and real-time public data. However, persistent criticism from patient advocates, independent researchers and technical experts suggests the new system may not address long-standing concerns about data transparency, thorough investigation, and ultimate accountability.

The effectiveness of AEMS will likely depend on whether the FDA incorporates mandatory reporting, ensures rigorous follow-up on submissions, and makes critical data sets like the Vaccine Safety Datalink publicly accessible. As the system expands through May 2026, its ability to restore public trust in post-market surveillance will be closely watched. ^[12][13]

References

1. FDA Launches New System to Track Product Safety Reports … – Facebook.
2. FDA Unveils New Vaccine Injury Tracking System — Is It Any Better Than … – Public Health Policy Journal.
3. Real-time Vaccine Injury Tracking System Aims to Address “Regulatory Malpractice” in U.S. Surveillance. – NaturalNews.com. Willow Tohi.
4. FDA Unveils New Platform For Tracking Side Effects. – The Epoch Times.
5. FDA Unveils New Vaccine Injury Tracking System — Is It Any Better Than the Old One? – The Defender. Michael Nevradakis.
6. FDA announces AEMS, new adverse-event database to replace … – CIDRAP.
7. FDA launches new AI-powered system to track drug and vaccine … – Yahoo! News.
8. The Silent Epidemic: How COVID-19 Vaccine Injuries Are Being Ignored on a Global Scale. – NaturalNews.com. Patrick Lewis.
9. CDC Runs Two VAERS Systems — The Public Can Access Only One of Them. – ChildrensHealthDefense.org.
10. Canary In a Covid World How Propaganda and Censorship Changed Our World.
11. Stroke Risk With Pfizer Shot Announced. – NaturalNews.com.
12. FDA consolidates adverse events reporting systems. – RAPS.
13. CDC admits VAERS captures only 1% of vaccine injuries: TIME to build a TRANSPARENT and HONEST vaccine monitoring system. – NaturalNews.com. Lance D Johnson.